The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

Suchan still needed chemotherapy and radiation, but Salgia credits Rybrevant for shrinking her tumors 60 to 70%. It specifically targets her cancer cells and revs up the immune system. For a year and ...

By Bhanvi Satija and Mariam Sunny Feb 26 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Boehringer ...

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival ...

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...

A targeted therapy called sevabertinib has been approved for patients with non-small cell lung cancer that carries an activating mutation in the HER2 gene.

A next-generation nanobody-liposome treatment slashes tumor growth by homing in on a key cancer marker, opening new doors for safer and more effective lung cancer therapy. Study: Targeting CD155 in ...

In the United States and elsewhere, there’s been a major shift in patients treated for lung cancer. As the percentage of people who smoke has declined over the decades, people who’ve never smoked have ...

By Priyanjana Pramanik, MSc. Researchers reveal why lung cancer in people who never smoked is increasing and explore how ...

This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...